JP7785696B2 - 操作されたｔ細胞受容体および使用の方法 - Google Patents

操作されたｔ細胞受容体および使用の方法

Info

Publication number
JP7785696B2
JP7785696B2 JP2022570271A JP2022570271A JP7785696B2 JP 7785696 B2 JP7785696 B2 JP 7785696B2 JP 2022570271 A JP2022570271 A JP 2022570271A JP 2022570271 A JP2022570271 A JP 2022570271A JP 7785696 B2 JP7785696 B2 JP 7785696B2
Authority
JP
Japan
Prior art keywords
tcr
seq
amino acid
polypeptide
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022570271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528255A5 (enExample
JP2023528255A (ja
Inventor
キャシアン イー
ケ パン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2023528255A publication Critical patent/JP2023528255A/ja
Publication of JP2023528255A5 publication Critical patent/JP2023528255A5/ja
Application granted granted Critical
Publication of JP7785696B2 publication Critical patent/JP7785696B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022570271A 2020-05-18 2021-05-17 操作されたｔ細胞受容体および使用の方法 Active JP7785696B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063026445P 2020-05-18 2020-05-18
US63/026,445 2020-05-18
PCT/US2021/032818 WO2021236548A1 (en) 2020-05-18 2021-05-17 Engineered t cell receptors and methods of use

Publications (3)

Publication Number Publication Date
JP2023528255A JP2023528255A (ja) 2023-07-04
JP2023528255A5 JP2023528255A5 (enExample) 2024-05-28
JP7785696B2 true JP7785696B2 (ja) 2025-12-15

Family

ID=78708026

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570271A Active JP7785696B2 (ja) 2020-05-18 2021-05-17 操作されたｔ細胞受容体および使用の方法

Country Status (8)

Country Link
US (1) US20230190812A1 (enExample)
EP (1) EP4153618A4 (enExample)
JP (1) JP7785696B2 (enExample)
CN (1) CN116322715A (enExample)
AU (1) AU2021276264A1 (enExample)
CA (1) CA3183663A1 (enExample)
TW (1) TWI907427B (enExample)
WO (1) WO2021236548A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3236237A1 (en) * 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
CN114149978B (zh) * 2022-02-09 2022-04-26 深圳博雅感知药业有限公司 制备car-t细胞的方法
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN120924527B (zh) * 2025-10-16 2026-02-06 内蒙古科为博生物科技有限公司 一种内切葡聚糖酶突变体eg06、其编码基因及其产品与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
JP2018531044A (ja) 2015-09-29 2018-10-25 アイレパートリー インコーポレイテッド 免疫レパートリーの正常性の評価方法およびその使用
WO2019036688A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
WO2019133853A1 (en) 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101773690B1 (ko) * 2007-03-05 2017-08-31 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 암 항원 특이적 ｔ 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용
CN102272153B (zh) * 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP3572510B1 (en) * 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
IL308831A (en) * 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
US20210061876A1 (en) * 2017-12-29 2021-03-04 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft T cell receptors for tumor specific proteasome splice variants and uses thereof
KR20200119840A (ko) * 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018108612A1 (de) * 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013002086A1 (ja) 2011-06-28 2013-01-03 株式会社癌免疫研究所 ペプチド癌抗原特異的ｔ細胞のレセプター遺伝子
JP2018531044A (ja) 2015-09-29 2018-10-25 アイレパートリー インコーポレイテッド 免疫レパートリーの正常性の評価方法およびその使用
WO2019036688A1 (en) 2017-08-18 2019-02-21 Gritstone Oncology, Inc. ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS
WO2019133853A1 (en) 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens

Also Published As

Publication number Publication date
WO2021236548A1 (en) 2021-11-25
TWI907427B (zh) 2025-12-11
EP4153618A1 (en) 2023-03-29
JP2023528255A (ja) 2023-07-04
TW202146438A (zh) 2021-12-16
US20230190812A1 (en) 2023-06-22
CA3183663A1 (en) 2021-11-25
AU2021276264A1 (en) 2022-12-22
EP4153618A4 (en) 2024-06-26
CN116322715A (zh) 2023-06-23

Similar Documents

Publication Publication Date Title
TWI907427B (zh) 經工程化之t細胞受體及其使用方法
US20240009241A1 (en) Engineered t cell receptors targeting egfr antigens and methods of use
JP2024539291A (ja) 神経膠芽腫を治療するための方法および組成物
WO2021222928A1 (en) Treatment and prevention of cancer using virus-specific immune cells expressing chimeric antigen receptors
TWI893070B (zh) 經工程化之t細胞受體及使用方法
JP7827645B2 (ja) 操作されたｔ細胞受容体および使用の方法
US20260125448A1 (en) Peptides and engineered t cell receptors targeting mage-a4 antigen and methods of use
US20250289866A1 (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
US20260007698A1 (en) Peptides and engineered t cell receptors targeting vcy antigen and methods of use
US20250073333A1 (en) Peptides and engineered t cell receptors targeting fanci, rad51, and pbk antigens and methods of use
WO2025096983A1 (en) Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use
WO2025101705A1 (en) Peptides and engineered t cell receptors targeting a melanoma antigen preferentially expressed in tumors antigen and methods of use
HK40113193A (en) Peptides and engineered t cell receptors targeting ndc80 antigen and methods of use
EP4716699A2 (en) Peptides and engineered t cell receptors targeting brachyury antigen and methods of use
HK40092477A (en) Engineered t cell receptors and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251203

R150 Certificate of patent or registration of utility model

Ref document number: 7785696

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150